Travere Therapeutics (TVTX) Tops Q4 EPS by 41c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.37, $0.41 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $129.69 million versus the consensus estimate of $145.23 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c